Dassault Systèmes has announced that Ion Beam Applications SA (IBA) — the leading medical device manufacturer and pioneer in proton beam therapy for cancer treatment — has selected the “Licensed to Cure for Medical Device” industry solution experience to support the development processes of its medical accelerator solutions.
Image credit: Dassault Systèmes / Facebook page
According to the press release by Dassault Systèmes, the “Licensed to Cure for Medical Device” industry solution experience is based on V6 architecture, and will optimise resource allocation and maximise capitalisation and design reuse.
The solution will also provide IBA with regulatory compliance, allowing its global teams to get a centralised access to the most up to date design, regulatory and quality information.
“With ‘Licensed to Cure for Medical Device’, we will have a single unifying development framework in which we can capitalise all our data, processes and methodologies for future reuse, and from there improve the productivity of all downstream processes,” said Thomas Canon, PLM Program Manager at IBA.
“Medical device manufacturers have a dual responsibility: to patients for innovative therapeutic solutions and to regulatory bodies that must ensure that their equipment abides by stringent safety and quality protocols. The integrated ‘Licensed to Cure for Medical Device’ industry solution experience gives the Life Science Industry a competitive means to provide a faster reply to operators’ needs and, ultimately, faster accessibility to therapies for the patients,” said Monica Menghini, Executive Vice President for Corporate Strategy, Industry and Marketing at Dassault Systèmes.
With the “Licensed to Cure for Medical Device” industry solution experience, IBA will also be able to maintain its competitive edge on the market.
The 3DEXPERIENCE Company is renowned world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions.
For more information on Dassault Systèmes’ industry solution experiences for the life sciences industry, please visit Life Sciences section.
